Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
OrthoPediatrics price target raised to $72 from $64 at Truist » 09:11
05/07/21
05/07
09:11
05/07/21
09:11
KIDS

OrthoPediatrics

$61.59 /

+5.4 (+9.61%)

Truist analyst Kaila Krum…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KIDS OrthoPediatrics
$61.59 /

+5.4 (+9.61%)

KIDS OrthoPediatrics
$61.59 /

+5.4 (+9.61%)

06:17 Today JMP Securities
OrthoPediatrics price target raised to $70 from $55 at JMP Securities
05/06/21 Piper Sandler
OrthoPediatrics price target raised to $70 from $62 at Piper Sandler
04/19/21 Truist
OrthoPediatrics price target raised to $64 from $54 at Truist
04/06/21 Piper Sandler
OrthoPediatrics price target raised to $62 from $55 at Piper Sandler
KIDS OrthoPediatrics
$61.59 /

+5.4 (+9.61%)

  • 18
    Jun
KIDS OrthoPediatrics
$61.59 /

+5.4 (+9.61%)

Initiation
Brooks Automation assumed with a Buy at Needham » 08:00
05/07/21
05/07
08:00
05/07/21
08:00
BRKS

Brooks Automation

$94.51 /

-0.25 (-0.26%)

Needham analyst David…

Needham analyst David Saxon assumed coverage of Brooks Automation with a Buy rating and $110 price target. The analyst expects the company to deliver margin upside driven primarily by its Life Sciences business as he estimates that Brooks Automation can produce double-digit earnings growth over the next few years.

ShowHide Related Items >><<
BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

04/05/21 B. Riley
Brooks Automation price target raised to $125 from $105 at B. Riley Securities
02/10/21 KeyBanc
Brooks Automation price target raised to $111 from $99 at KeyBanc
02/03/21 Credit Suisse
Brooks Automation price target raised to $70 from $58 at Credit Suisse
02/03/21 B. Riley
Brooks Automation price target raised to $105 from $100 at B. Riley Securities
BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

BRKS Brooks Automation
$94.51 /

-0.25 (-0.26%)

Earnings
Sutro Biopharma reports Q1 EPS (66c), consensus (60c) » 07:10
05/07/21
05/07
07:10
05/07/21
07:10
STRO

Sutro Biopharma

$18.50 /

-0.81 (-4.19%)

Reports Q1 revenue…

Reports Q1 revenue $14.7M, consensus $5.73M. As of March 31, Sutro had cash, cash equivalents and marketable securities of $294.9M vs. $326.5M as of December 31, 2020, with projected runway into the second half of 2023. "We are enthusiastic about the meaningful clinical benefit of STRO-002, our FolRalpha-targeting Antibody-Drug Conjugate (ADC), for women with advanced ovarian cancer, as demonstrated by the Phase 1 dose-escalation data, and look forward to providing follow-up data at ASCO," said Bill Newell, Sutro's Chief Executive Officer. "We continue to enroll patients for the dose-expansion portion of the Phase 1 study and we have activated additional clinical sites. STRO-002 is one of the four product candidates in the clinic that were discovered, developed, and are manufactured using our proprietary and integrated cell-free protein synthesis platform. We intend to continue creating value by leveraging our platform to deliver on therapeutics that are precise, rationally designed, and homogenous, for a broad set of patients with unmet medical needs."

ShowHide Related Items >><<
STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

01/28/21 Truist
Sutro Biopharma price target raised to $37 from $24 at Truist
12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
  • 09
    Dec
  • 12
    May
STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

STRO Sutro Biopharma
$18.50 /

-0.81 (-4.19%)

Recommendations
OrthoPediatrics price target raised to $70 from $55 at JMP Securities » 06:17
05/07/21
05/07
06:17
05/07/21
06:17
KIDS

OrthoPediatrics

/

+

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KIDS OrthoPediatrics
/

+

KIDS OrthoPediatrics
/

+

05/06/21 Piper Sandler
OrthoPediatrics price target raised to $70 from $62 at Piper Sandler
04/19/21 Truist
OrthoPediatrics price target raised to $64 from $54 at Truist
04/06/21 Piper Sandler
OrthoPediatrics price target raised to $62 from $55 at Piper Sandler
12/03/20 Stifel
Stifel says short report claims about OrthoPediatrics 'overstated,' 'inaccurate'
KIDS OrthoPediatrics
/

+

  • 18
    Jun
KIDS OrthoPediatrics
/

+

Yesterday
Earnings
Alphatec sees FY21 revenue $190M, consensus $179.79M » 17:11
05/06/21
05/06
17:11
05/06/21
17:11
ATEC

Alphatec

$15.23 /

-0.17 (-1.10%)

The Company expects total…

The Company expects total revenue for the fiscal year ended December 31, 2021, to approximate $190 million, which includes U.S. revenue of approximately $188 million. Revenue guidance reflects expected U.S. revenue growth of roughly 33% compared to 2020, driven by continued launches of novel procedures, products, and the revitalization of the Company's distribution network. Total revenue guidance contemplates the anticipated wind-down of the Company's international supply agreement on August 31, 2021. ATEC expects to update guidance to reflect the positive impact of EOS imaging when the Company reports second quarter 2021 financial results, once the transaction is finalized.

ShowHide Related Items >><<
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

04/08/21 Piper Sandler
Alphatec CFO change 'surprising but manageable,' says Piper Sandler
03/05/21 H.C. Wainwright
Alphatec price target raised to $19 from $16 at H.C. Wainwright
03/05/21 Piper Sandler
Alphatec price target raised to $19 from $17 at Piper Sandler
01/29/21 Piper Sandler
Alphatec price target raised to $17 from $12 at Piper Sandler
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

  • 14
    Oct
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

Earnings
Alphatec reports Q1 EPS (26c), consensus (20c) » 17:09
05/06/21
05/06
17:09
05/06/21
17:09
ATEC

Alphatec

$15.23 /

-0.17 (-1.10%)

Reports Q1 revenue…

Reports Q1 revenue $44.1M, consensus $41.05M. "With revenue growth of 50% in the first quarter, ATEC's market share expansion continues," said Pat Miles, Chairman and Chief Executive Officer. "Our relentless focus on improving the clinical experience in spine is now propelling industry-leading growth. Market-shaping innovation, integrated with unprecedented intra-operative information, is compelling an increasing number of surgeons and exclusive distributors to partner with ATEC. That growth is being amplified as the introduction of distinct products and procedures throughout our portfolio increases revenue per surgery and inspires broader adoption. Still, there is vast opportunity ahead of us to advance spine surgery, and as spine's most experienced students, we know that ATEC's best is yet to come!"

ShowHide Related Items >><<
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

04/08/21 Piper Sandler
Alphatec CFO change 'surprising but manageable,' says Piper Sandler
03/05/21 H.C. Wainwright
Alphatec price target raised to $19 from $16 at H.C. Wainwright
03/05/21 Piper Sandler
Alphatec price target raised to $19 from $17 at Piper Sandler
01/29/21 Piper Sandler
Alphatec price target raised to $17 from $12 at Piper Sandler
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

  • 14
    Oct
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

Earnings
Alphatec reports Q1 EPS (26c), consensus (20c) » 17:09
05/06/21
05/06
17:09
05/06/21
17:09
ATEC

Alphatec

$15.23 /

-0.17 (-1.10%)

Reports Q1 revenue…

Reports Q1 revenue $44.1M, consensus $41.05M. "With revenue growth of 50% in the first quarter, ATEC's market share expansion continues," said Pat Miles, Chairman and Chief Executive Officer. "Our relentless focus on improving the clinical experience in spine is now propelling industry-leading growth. Market-shaping innovation, integrated with unprecedented intra-operative information, is compelling an increasing number of surgeons and exclusive distributors to partner with ATEC. That growth is being amplified as the introduction of distinct products and procedures throughout our portfolio increases revenue per surgery and inspires broader adoption. Still, there is vast opportunity ahead of us to advance spine surgery, and as spine's most experienced students, we know that ATEC's best is yet to come!"

ShowHide Related Items >><<
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

04/08/21 Piper Sandler
Alphatec CFO change 'surprising but manageable,' says Piper Sandler
03/05/21 H.C. Wainwright
Alphatec price target raised to $19 from $16 at H.C. Wainwright
03/05/21 Piper Sandler
Alphatec price target raised to $19 from $17 at Piper Sandler
01/29/21 Piper Sandler
Alphatec price target raised to $17 from $12 at Piper Sandler
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

  • 14
    Oct
ATEC Alphatec
$15.23 /

-0.17 (-1.10%)

Earnings
Cardiovascular Systems sees Q4 revenue $67M-$70M, consensus $69.78M.  16:52
05/06/21
05/06
16:52
05/06/21
16:52
CSII

Cardiovascular Systems

$38.99 /

-0.6 (-1.52%)

 
ShowHide Related Items >><<
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

  • 10
    Jun
Earnings
Cardiovascular Systems reports Q3 EPS (15c), consensus (10c) » 16:51
05/06/21
05/06
16:51
05/06/21
16:51
CSII

Cardiovascular Systems

$38.99 /

-0.6 (-1.52%)

Reports Q3 revenue…

Reports Q3 revenue $63.3M, consensus $63.12M. CEO Scott Ward says: "Third quarter revenues increased 3.4% to $63.3 million and were led by our coronary franchise, due to strong procedure volume domestically, increased sales of procedure support products, and growing adoption of orbital atherectomy internationally. Peripheral revenues were flat as patients with claudication continued to defer evaluation and treatment. Office-based labs purchased nearly one-half of our peripheral unit volume during the quarter demonstrating that an increased number of complex peripheral procedures were performed outside the hospital. Throughout the pandemic, we have seen the OBL become another viable option for complex procedures, which we expect to continue even as the pandemic subsides. As we head into our fourth quarter, we believe the majority of markets we serve have either returned to pre-Covid procedure levels or are poised to do so in the very near future."

ShowHide Related Items >><<
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

12/16/20 Northland
Cardiovascular Systems price target raised to $45 from $40 at Northland
08/17/20 Barclays
Cardiovascular Systems offers 'significant upside opportunity,' says Barclays
07/22/20
Fly Intel: Top five analyst initiations
07/22/20 Northland
Cardiovascular Systems initiated with an Outperform at Northland
CSII Cardiovascular Systems
$38.99 /

-0.6 (-1.52%)

  • 10
    Jun
Earnings
Athersys reports Q1 EPS (13c), consensus (9c) » 16:24
05/06/21
05/06
16:24
05/06/21
16:24
ATHX

Athersys

$1.56 /

-0.02 (-1.27%)

Reports Q1 revenue $0,…

Reports Q1 revenue $0, consensus $420K. "Since our recent call, we remain on track with respect to our operating plans," stated Mr. William (B.J.) Lehmann, Jr., InterimCEO of Athersys. "We look forward to important progress during the remaining course of the year, including expected top-line results from the TREASURE and ONE-BRIDGE studies in Japan. Additionally, we remain focused on important priorities for the year, which include advancing our MASTERS-2 study and other clinical programs, supporting our partner, Healios, as it prepares for important regulatory applications, and in further developing our commercial manufacturing processes and planning."

ShowHide Related Items >><<
ATHX Athersys
$1.56 /

-0.02 (-1.27%)

ATHX Athersys
$1.56 /

-0.02 (-1.27%)

02/17/21 Dawson James
Athersys management transition, standstill are positives, says Dawson James
06/25/20 BofA
Athersys initiated with a Buy at BofA
06/25/20 BofA
Athersys initiated with a Buy at BofA
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
ATHX Athersys
$1.56 /

-0.02 (-1.27%)

ATHX Athersys
$1.56 /

-0.02 (-1.27%)

ATHX Athersys
$1.56 /

-0.02 (-1.27%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.